Comparison of goserelin and leuprorelin for ovarian protection during chemotherapy in young patients with breast cancer

Kim, Sung Eun; Kim, Won-Ji; Choi, DooSeok; Lee, Dong-Yun

doi:10.1007/s10549-023-06877-4

Cited by 6 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kim et al [ 282 ] demonstrated that goserelin’s ability to protect the ovaries during cyclophosphamide- and doxorubicin-based chemotherapy in a group of patients younger than 40 years old with breast cancer was comparable to that demonstrated by leuprorelin (leuprolide acetate). An analysis of clinical trials among Asian breast cancer patients confirmed that leuprorelin could preserve ovarian function, reduce symptoms of ovarian failure, prevent the occurrence of early menopause, and shorten the time to the resumption of menstruation [ 283 ].…”

Section: Potential Ovarian-protective Mechanismsmentioning

confidence: 97%

Gynotoxic Effects of Chemotherapy and Potential Protective Mechanisms

Markowska,

Antoszczak,

Markowska

et al. 2024

Cancers

View full text Add to dashboard Cite

Chemotherapy is one of the leading cancer treatments. Unfortunately, its use can contribute to several side effects, including gynotoxic effects in women. Ovarian reserve suppression and estrogen deficiency result in reduced quality of life for cancer patients and are frequently the cause of infertility and early menopause. Classic alkylating cytostatics are among the most toxic chemotherapeutics in this regard. They cause DNA damage in ovarian follicles and the cells they contain, and they can also induce oxidative stress or affect numerous signaling pathways. In vitro tests, animal models, and a few studies among women have investigated the effects of various agents on the protection of the ovarian reserve during classic chemotherapy. In this review article, we focused on the possible beneficial effects of selected hormones (anti-Müllerian hormone, ghrelin, luteinizing hormone, melatonin), agents affecting the activity of apoptotic pathways and modulating gene expression (C1P, S1P, microRNA), and several natural (quercetin, rapamycin, resveratrol) and synthetic compounds (bortezomib, dexrazoxane, goserelin, gonadoliberin analogs, imatinib, metformin, tamoxifen) in preventing gynotoxic effects induced by commonly used cytostatics. The presented line of research appears to provide a promising strategy for protecting and/or improving the ovarian reserve in the studied group of cancer patients. However, well-designed clinical trials are needed to unequivocally assess the effects of these agents on improving hormonal function and fertility in women treated with ovotoxic anticancer drugs.

show abstract

Section: Potential Ovarian-protective Mechanismsmentioning

confidence: 97%

Gynotoxic Effects of Chemotherapy and Potential Protective Mechanisms

Markowska,

Antoszczak,

Markowska

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…To date, the addition of GnRHa to chemotherapy is recommended by international guidelines as a standard strategy for ovarian function preservation in premenopausal patients affected by breast cancer [ 5 , 36 – 38 ]. Goserelin and leuprorelin seem to be equally effective in terms of ovarian protection in young patients affected by breast cancer administered with chemotherapy [ 39 ]. No data are available regarding the comparison head-to-head between triptorelin and other GnRHa agents.…”

Section: Indications To Ofs In Early Breast Cancermentioning

confidence: 99%

Ovarian Suppression: Early Menopause and Late Effects

Molinelli,

Jacobs,

Nader-Marta

et al. 2024

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Opinion statementAround 90% of breast tumours are diagnosed in the early stage, with approximately 70% being hormone receptor-positive. The cornerstone of adjuvant therapy for early-stage hormone receptor-positive breast cancer is endocrine therapy, tailored according to disease stage, biological characteristics of the tumour, patient’s comorbidities, preferences and age. In premenopausal patients with hormone receptor-positive breast cancer, ovarian function suppression is a key component of the adjuvant endocrine treatment in combination with an aromatase inhibitor or tamoxifen. Moreover, it can be used during chemotherapy as a standard strategy for ovarian function preservation in all breast cancer subtypes. In the metastatic setting, ovarian function suppression should be used in all premenopausal patients with hormone receptor-positive breast cancer to achieve a post-menopausal status. Despite its efficacy, ovarian function suppression may lead to several side effects that can have a major negative impact on patients’ quality of life if not properly managed (e.g. hot flashes, depression, cognitive impairment, osteoporosis, sexual dysfunction, weight gain). A deep knowledge of the side effects of ovarian function suppression is necessary for clinicians. A correct counselling in this regard and proactive management should be considered a fundamental part of survivorship care to improve treatment adherence and patients’ quality of life.

show abstract

“…The number of follicles is an indicator of ovarian reserve in the ovary. The ultrastructural indicators of chemotherapy-induced ovarian damage are diffuse follicle loss and ovarian fibrosis [3,4]. Alkylating agents are the substances that cause the highest follicle loss.…”

Section: Introductionmentioning

confidence: 99%

Protective effect of Spirulina in the ovary of rats against Doxorubicin toxicity

Öztürk,

İrkin

2024

RC FCV-LUZ

View full text Add to dashboard Cite

Doxorubicin (Dox) is an anti–cancer agent used of ovarian, breast, liver, lung cancers and solid tumors such as leukemia and lymphoma treatment. However, since it is an antineoplastic agent with a high toxic effect, it causes toxicity on many organs and tissues in the organism. Spirulina spp. (SP) contains phytopigments such as β–carotene, tocopherols and xanthophylls and is a natural source of vitamin A as well as its anticarcinogenic effect. For these reasons, this study was planned to experimentally reveal the antioxidant and protective effects of SP on Dox–induced reproductive toxicity in female rats. In the study, histopathological evaluation was performed after Hematoxylin–Eosin staining in female rats with Dox toxicity. The distribution of GSK–3β for cell proliferation, HIF–1α for oxidative stress and VEGF for vascularization were evaluated. TUNEL staining was performed to determine apoptosis. It was determined that SP prevented tissue damage on the ovarian tissue of rats with Dox toxicity, and this positive effect was achieved through factors such as oxidative stress (HIF–1α), vascularization (VEGF) and inhibition of cell death (Apoptosis). It has been observed that SP treatment to be applied after chemotherapy is effective in protecting both the developing follicles and the primordial follicle pool.

show abstract

Comparison of goserelin and leuprorelin for ovarian protection during chemotherapy in young patients with breast cancer

Cited by 6 publications

References 31 publications

Gynotoxic Effects of Chemotherapy and Potential Protective Mechanisms

Gynotoxic Effects of Chemotherapy and Potential Protective Mechanisms

Ovarian Suppression: Early Menopause and Late Effects

Protective effect of Spirulina in the ovary of rats against Doxorubicin toxicity

Contact Info

Product

Resources

About